Avalon Globocare (Avalon Globocare) Change In Working Capital : $-0.03 Mil (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Avalon Globocare Change In Working Capital?

Avalon Globocare's change in working capital for the quarter that ended in Dec. 2023 was $0.10 Mil.

Avalon Globocare's change in working capital for the fiscal year that ended in Dec. 2023 was $-0.04 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Avalon Globocare Change In Working Capital Historical Data

The historical data trend for Avalon Globocare's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avalon Globocare Change In Working Capital Chart

Avalon Globocare Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

1.64

-0.86

1.50

0.21

-0.04

Avalon Globocare Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Working Capital	Get a 7-Day Free Trial															0.17	0.53	-0.82	0.15	0.10

Avalon Globocare Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.03 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Avalon Globocare Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Avalon Globocare's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Avalon Globocare (Avalon Globocare) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Real Estate » Real Estate » Avalon Globocare Corp (NAS:ALBT) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

4400 Route 9 South, Suite 3100, Freehold, NJ, USA, 07728

Website

https://www.avalon-globocare.com

Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. It has two reportable segments: the real property operating segment which is the key revenue driver; medical-related consulting services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.

Executives

Lourdes Felix	director	15 CALLE VERANO, RANCHO SANTA MARGARITA CA 92688
W J Tauzin	director	901 HUGH WALLIS ROAD S, LAFAYETTE LA 70508
Wenzhao Lu	director, 10 percent owner	C/O GLOBAL TECHNOLOGIES CORP., 3 SOUTH STREET, SUITE 101, FREEHOLD NJ 97728
Steven Andrew Sanders	director	431 EAST 20TH STREET, NEW YORK NY 10010
Yancen Lu	director	14009 SE 50TH STREET, BELLEVUE WA 98006
Stilley William B. Iii	director	1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Tevi Troy	director	611 SOMERSWORTH WAY, SILVER SPRING MD 20902
Luisa Ingargiola	officer: Chief Financial Officer	4826 BLUE JAY CIRCLE, PALM HARBOR FL 34683
David Jin	director, officer: CEO and President	C/O GLOBAL TECHNOLOGIES CORP., 3 SOUTH STREET, SUITE 101, FREEHOLD NJ 97728
Yue Charles Li	director	C/O AVALON GLOBOCARE CORP., 4400 ROUTE 9 SOUTH, SUITE 3100, FREEHOLD NJ 07728
Meng Li	director, officer: Chief Operating Officer	C/O GLOBAL TECHNOLOGIES CORP., 3 SOUTH STREET, SUITE 101, FREEHOLD NJ 97728
Steven Philip Sukel	director	33 ALPINE DRIVE, MORGANVILLE NJ 07751